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Limited availability of Indian rhesus macaques (IRM) is a bottleneck to study Zika virus
(ZIKV) pathogenesis and evaluation of appropriate control measures in non-human
primates. To address these issues, we report here the Mauritian cynomolgus macaque
(MCM) model for ZIKV infection. In brief, six MCMs (seronegative for Dengue and ZIKV)
were subdivided into three cohorts with a male and female each and challenged with
different doses of Asian [PRVABC59 (Puerto Rico) or FSS13025 (Cambodia)] or African
(IBH30656) lineage ZIKV isolates. Clinical signs were monitored; and biological fluids
(serum, saliva, and urine) and tissues (testes and brain) were assessed for viral load by
quantitative reverse transcription polymerase chain reaction and neutralizing antibodies
(Nab) by 50% Plaque Reduction Neutralization Test (PRNT50) at various times post-
infection (p.i). PRVABC59 induced viremia detectable up to day 10, with peak viral
load at 2–3 days p.i. An intermittent viremia spike was observed on day 30 with titers
reaching 2.5 × 103 genomes/mL. Moderate viral load was observed in testes, urine and
saliva. In contrast, FSS13025 induced viremia lasting only up to 6 days and detectable
viral loads in testes but not in urine and saliva. Recurrent viremia was detected but at
lower titers compare to PRVABC59. Challenge with either PRVABC59 or FSS13025
resulted in 100% seroconversion; with mean PRNT50 titers ranging from 597 to 5179.
IBH30656 failed to establish infection in MCM suggesting that MCM are susceptible to
infection with ZIKV isolates of the Asian lineage but not from Africa. Due to the similarity
of biphasic viremia and Nab responses between MCM and IRM models, MCM could be
a suitable alternative for evaluation of ZIKV vaccine and therapeutic candidates.
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INTRODUCTION
Zika virus (ZIKV) is a flavivirus transmitted primarily through mosquitos, first reported in 1947
(reviewed in Plourde and Bloch, 2016). Though it was initially restricted to Africa and Asia,
in the last couple of years increasing cases have been observed in as many as 70 countries
worldwide. Though apparent clinical symptoms are reported only in 20% of the infected patients,
the disease associated complications such as microcephaly in newborn children and neurological
manifestations (Guillain–Barre syndrome) make ZIKV a major health concern. Considering the
rapid spread and the associated disease complications, the World Health Organization (WHO) has
recently declared ZIKV as a global health emergency. This health scare is compounded by the lack
of effective prophylactic and therapeutic measures.
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Currently, immune compromised mouse (Brault et al., 2016;
Cugola et al., 2016; Dowall et al., 2016; Lazear et al., 2016;
Zmurko et al., 2016) and rhesus macaque models (Abbink et al.,
2016; Dudley et al., 2016) have been used for studies on the
natural history and pathogenesis of ZIKV infection. Type-I
interferon receptor deficient AG129 mice but not the parent
129Sv/Ev strain of mice were found to be susceptible to a
lethal ZIKV infection (Dowall et al., 2016). Lazear et al. (2016)
reported the development of neurological disease in IFNar1
(−/−) mice and IRF3, 5, and 7 triple knockout mice (Lazear
et al., 2016). The AG129 model was also helpful in evaluating
the antiviral activity of viral polymerase inhibitor 7-deaza-2′-
C-methyladenosine (7DMA) (Zmurko et al., 2016). Using the
Swiss Jim Lambert (SJL) mouse model, Cugola et al. (2016)
were able to demonstrate fetal infection and microcephaly with
a Brazilian strain of Zika virus. Though mouse models are
easily accessible, non-human primates (NHPs) are an attractive
model for ZIKV research and drug discovery due to their close
similarity with humans. NHP models could provide invaluable
information regarding mechanism of action, efficacy and safety
of both drug and vaccine candidates and allow optimization of
the product, dose and route as observed previously for HIV
vaccines (Spearman, 2006). Rhesus macaques were shown to be
susceptible to an Asian lineage of ZIKV (Dudley et al., 2016),
with pregnant animals being viremic for longer period compared
to non-pregnant animals. Evaluation of three vaccine candidates
in rhesus monkeys successfully protected them against ZIKV
challenge (Abbink et al., 2016).
The use of a number of non-rhesus macaque species, especially
cynomolgus macaques, as a model for human infectious diseases
has increased in recent years (Antony and MacDonald, 2015).
This is mostly due to the reduced availability of Rhesus monkeys
consequent to the ban on their export from India. Compared to
Rhesus macaques, Cynomolgus macaques offer the advantages
of smaller size and weight (Andrade et al., 2004), resulting
in reduced amounts of drugs needed for studies administered
on body weight basis. Smaller animal size also provides the
additional benefit of easier animal husbandry practices (such as
handling, space requirements, etc.), translating into significant
cost-benefit. Considering these factors, we conducted a limited
study (N = 2/group) to evaluate the suitability of cynomolgus
monkeys as a potential alternative NHP model for ZIKV
infection. Using a systematic approach of infection with ZIKV
strains of different geographical origin, we demonstrate that
cynomolgus monkeys can be successfully infected with ZIKV
of Asian-lineage including isolates recently emerging in the
current pandemic of the Americas, but not strains of African
lineage.
MATERIALS AND METHODS
Care and Use of Animals
This study was designed to use the fewest number of animals
possible, consistent with the objective of the study, the scientific
needs, contemporary scientific standards, and in consideration
of applicable regulatory requirements. This study design was
reviewed by the IACUC at Southern Research Institute and
was approved on 04/21/2016; it was assigned IACUC tracking
number 16-03-014F. Animals were socially housed during the
quarantine phase and single housed following the Day 0
challenge. Animals were housed in stainless steel cages that meet
requirements as set forth in the Animal Welfare Act (Public Law
99-198) and the Guide for the Care and Use of Laboratory Animals
(8th Edition, Institute of Animal Resources, Commission on
Life Sciences, National Research Council; National Academy
Press; Washington D.C.; 2011). Animals were housed in an
environmentally monitored and ventilated room. Fluorescent
lighting provided illumination approximately 12 h per day.
The objective of this pilot proof of concept study was to
evaluate the susceptibility of cynomolgus macaques to ZIKV
of different geographic origins and did not involve statistical
comparison between groups of animals. We’ve selected two
monkeys per challenge strain and this is deemed sufficient to
provide enough data to monitor immunological and virological
endpoints against each strain. The use of two animals per
strain is the minimum number sufficient to achieve the research
goals. Based on the results obtained from this pilot study,
statistically relevant sample size will be determined for future
GLP studies.
Orchiectomy Surgery
The animals were initially given either atropine (0.02–0.04 mg/kg
IM) to control respiratory secretions, then sedated with
ketamine (10–50 mg/kg IM). Ketamine was followed by xylazine
(0.30 mg/kg IM) for induction. The animals were then intubated,
placed on a portable isoflurane machine, and isoflurane (0.5–
5.0%) was used to bring the animals to the desired plane
of anesthesia for the procedure. Anesthesia was maintained
using approximately 1–3% isoflurane throughout the procedure.
Before the initial incision, ketoprofen (2.2 mg/kg IM, SID) and
buprenorphine (0.01–0.03 mg/kg IM, BID) were administered.
A lidocaine/bupivacaine local block (at no more than 1.0 mg/kg
of each agent) was given at the incision area before surgery
began. Orchiectomy was performed to one testes per day. After
surgery, animals were removed from the isoflurane machine and
placed on towels/blankets with a warming system (Bair-Hugger
mat) and monitored until they recovered their swallowing reflex.
At this time, the endotracheal tube was removed and the
animal was returned to its home cage. Animals were observed
continually by trained technicians until they were able to sit
upright, at which time they were considered to have recovered
from the anesthesia. Ketoprofen (2.2 mg/kg IM, SID) and
buprenorphine (0.01–0.03 mg/kg IM, BID) were given as post-
operative analgesia for at least 2 days following the day of
surgery.
Sequence Analysis
Comparative ZIKV genomic sequence analysis and alignments
were performed using the NCBI BLAST Suite1. The “Megablastn,
Blastn” programs were used for the genomic comparisons and
“Primer-blast” for sequence specific primer homology analysis.
1http://www.ncbi.nlm.nih.gov/pubmed
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Viruses and Cell Culture
Vero cells (ATCC, CCL81) were grown in Dulbecco’s Minimal
Essential Medium (DMEM, Lonza), supplemented with 10%
fetal bovine serum (FBS), NEAA and L-Glutamine according to
standard culture conditions. ZIKV strains were obtained from the
following sources: IBH30656 (BEI Resources), PRVABC59 (CDC,
Division of Vector-borne Infectious Diseases) and FSS13025
(UTMB Arbovirus Reference Collection). In addition, the
following ZIKV isolates were used as reference strains for
comparative sequence analysis: ZKV2015 (Genbank Accession
#KU497555.1) (Calvet et al., 2016), Brazilian isolate Natal RGN,
Bahia, Brazil (Seq. Accession# KU527068.1) (Calvet et al., 2016;
Mlakar et al., 2016). Viral stocks of each strain were amplified in
Vero cells and quantitated according to the standard plaque assay
methodology.
Primers and Probes
Polymerase chain reaction (PCR) primers were designed to
the NS1 region of the ZIKV genome, proximal to those
described (Lanciotti et al., 2008) with modified target sequences
enabling the detection of isolates PRVABC59 Puerto Rico (Asian
lineage) and FSS13025 Cambodia (Asian lineage), IBH30656
Nigeria (African lineage). Primer and probe sequences are
provided in Goebel et al. (2016). Primer and probe sequences
were characterized for compatible melting temperatures (Tm),
self-dimer and hairpin potential using the Integrated DNA
Technologies (IDT, Coralville, IA) “Primer Analysis software”
tool. All the primers and probes were synthesized at IDT
Technologies. All primers were subjected to sequence analysis
including specific ZIKV strain homology and hybridization
potential across different clades. The probe has a 5′ 6-FAM
reporter and an internal (9th position) ZEN quencher and a 3′
IBFQ Iowa black quencher. Primers and protocols used for the
generation of the RNA template used for the standard curve
for absolute quantitation were as described in Goebel et al.
(2016).
Quantitative RT-PCR
Viral RNA was extracted from biological fluid samples (serum,
urine, and saliva) and tissue samples, including testes and
brain. Blood samples for serum were collected from anesthetized
animals on 1–4, 6, 8, 10, 14, 30, and 60 days post-infection
(p.i). Urine and oral swab saliva samples were collected on 1–
4, 6, 8, 10, 14 days p.i. Urine samples were collected from
anesthetized animals by catheterization or cystocentesis. Urine
was not successfully collected at all time points, especially from
females (indicated in Table 1). Saliva samples were obtained
by swabbing the oral cavity with a cotton swab, followed by
emersion of the swab into 2 mL PBS without Calcium and
Magnesium (Lonza, 17-512F). Briefly, using the QIAmp Viral
RNA Mini kit (Qiagen, 52906) total RNA was extracted and
purified from a total biological sample volume of 140 µl (as
per manufacturer) and eluted into 60 µL of nuclease free water
(Ambion, AM9939). Total RNA was extracted from tissues
samples as per manufacturer using the RNeasy Lipid Tissue mini
kit (Qiagen, 74804). Briefly, several (100–150 mg) sections were
dissected from each tissue sample. Tissue sections were subjected
to mechanical tissue homogenization in 1 mL of QIAzol Lysis
Reagent (Qiagen, 1023537) using a handheld tissue homogenizer
(Omni International) fitted with a rotor stator. Purified RNA was
eluted in 50 µL nuclease free water.
Five µl of purified RNA from each test article was used in a
20 µl qRT-PCR reaction consisting of Fast Virus 4x Master Mix
(Applied Biosystems, 4444436) containing 500 nM forward and
reverse primers and 200 nM probe. Cycling parameters included
an initial reverse transcription (RT) for 5 min at 53◦C, followed
by 1 min at 95◦C and 45 cycles of two step cycling at 95◦C for 5 s
and 60◦C for 50 s. A standard curve using positive control RNA
template was established over a dynamic range of 6-logs (106–
101) with each dilution in triplicate for absolute quantitation of
test samples. The Ct values obtained for each of the 6 log dilutions
indicate each strain specific primer probe set to be consistently
within 1 Ct of each other. Furthermore, each of the strain specific
primer and probe sets for the qRT-PCR reaction were found
to have a very similar lower limit of quantitation (LLOQ) with
values of no more than 10 copies/reaction or 500 copies/mL (data
not shown).
Statistics
The mean viral genome copies found in 4 and 8 day p.i.
teste samples were compared by one-way analysis of variance
(ANOVA) followed by Bonferroni’s multiple comparison test.
Differences in means were considered statistically significant for
a p-value < 0.05.
Plaque Reduction Neutralization Test
(PRNT50)
Briefly, Vero cells seeded at a concentration of approximately
3 × 105 cells/mL in 24-well plates were incubated for
approximately 24 h. Day of assay, input virus (PRVABC59) and
serially diluted serum samples were mixed and incubated for
1 h at 37 ± 1◦C in the dilution plate. Supernatant from cell-
seeded 24-well plates was decanted, then 100 µl of virus/serum
mixture was transferred from the dilution plate to the cells. After
1 h adsorption, agarose-containing overlay media was added and
plates were incubated at 37 ± 1◦C, 5% CO2 for 3 days. The
cells were fixed and stained using crystal violet solution and
plaques were counted visually. The neutralizing antibody titer
was expressed as the highest test serum dilution for which the
virus infectivity is reduced by 50%.
RESULTS
Cohorts
A total of six cynomolgus macaques, seronegative for Dengue
and ZIKV by ELSIA were subdivided in three cohorts,
each containing a male and female. Animals were inoculated
subcutaneously with ZIKV from either the Asian lineage (Puerto
Rico isolate; PRVABC59, or Cambodian isolate; FSS13025) or an
African lineage (Nigerian isolate; IBH30656). Male and female
animals were inoculated on Day 0 with 5.0 × 105 PFU and
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TABLE 1 | Virus shedding in urine and saliva.
Urine Oral Swabs
PRVABC59 FSS13025 IBH30656 PRVABC59 FSS13025 IBH30656
Day #5262M #5258F #5260M #5259F #5261M #5257F #5262M #5258F #5260M #5259 #5261M #5257F
1 0 0 0 N/C 0 N/C 0 0 0 1.6 N/T N/T
2 265 0 N/C N/C 43 N/C 105 0 0 0 N/T N/T
3 0 0 19 N/C N/C N/C 198 0 52 0 N/T N/T
4 0 N/C N/C N/C 0 N/C 169 146 0 1 N/T N/T
6 0 29 0 N/C 0 N/C 0 0 6.6 2 N/T N/T
8 0 0 N/C N/C 0 N/C 138 142 0 81 N/T N/T
10 0 87 0 N/C 200 N/C 244 0 12 0 N/T N/T
14 0 114 N/C N/C 0 N/C 109 359 0 0 N/T N/T
N/C, not collected; N/T, not tested.
1.0× 104 PFU, respectively. Previous studies have shown viremia
in cynomologus macaques following infection with similar
concentrations of Dengue virus. Additionally, natural levels
of West Nile Virus (WNV) transmission through a mosquito
“bite” reportedly range between 1.0 × 104 and 1.0 × 106 PFU
(Styer et al., 2007; Cox et al., 2012). Biological fluids (serum,
salvia, and urine) were collected at various times between 1
and 60 days p.i. Selected tissue samples were also collected
including testes on days 4 and 8 and brain tissue upon animal
sacrifice at study termination on day 60. Samples were assessed
for viral load and shedding using reverse transcription followed
by quantitative PCR (qRT-PCR) and immunological responses
were assessed using the 50% Plaque Reduction Neutralization
Test (PRNT50).
Clinical Observations
One animal challenged with IBH30656 developed a
slight erythema around the injection site (Draize dermal
score of 1) on study days 8 and 10. The erythema had
resolved by day 14. No clinical symptoms were observed
in any of the other animals during the course of the
study.
Serum Viral Load Analysis
Viral load was determined by qRT-PCR in serum recovered
from blood collected on days 1–4, 6, 8, 10, 14, 30, and 60.
Both cohorts challenged with Asian lineage strains, PRVABC59
or FSS13025, resulted in substantial viral load that peaked
between 2 and 3 days p.i. Maximal serum load for the
PRVABC59 challenge (high/low dose) was (1.4 × 105/8.9 × 103)
genome copies/mL and for FSS13025 (1.7 × 104/1.8 × 104)
copies/mL (Figure 1). However, the cohort infected with
the African lineage strain IBH30656 failed to produce a
“productive” infection as viral load peaked 3 day p.i. at
less than 100 copies/mL, well below our defined LLOQ
detection.
FIGURE 1 | Viral load in the serum of ZIKV infected cynomolgus macaques. Animals were grouped into three cohorts, each containing a male (opened
symbols) and female (closed symbols). Each cohort was challenged with ZIKV isolates at the dose indicated with either PRVABC59 (•), FSS13025 (N), or IBH30656
(). The serum viral load was determined using qRT-PCR at various days p.i. Notably, the serum viral load peaks around day 2–3 p.i. The LLOQ was previously
determined to be 500 copies/mL and is indicated by the black dashed line.
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Viral Clearance
Shortly after peaking at 2 or 3 days p.i., serum viremia diminished
over the course of about 10 days depending on the virus. By
14 days p.i. all viral loads were below the LLOQ of the qRT-PCR
assay at 500 copies/mL. Interestingly, we observed a consistent
viral load rebound of about 2 log by 30 day p.i. in three of
the four animals infected with either of the two Asian lineage
strains. This viral load rebound from serum samples is consistent
with that previously reported from a ZIKV challenge in rhesus
macaques (Dudley et al., 2016). In cynomolgus macaques the
rebound seems to persist longer, at least through day 30 p.i. which
was the only intermediate viral load test point between day 14
and the study termination at day 60. Viremia associated with the
later viral load rebound diminished to less than 100 copies/mL by
60 days p.i. (Figure 1).
Viral Shedding in Body Fluids
In contrast to the robust amounts of virus found in the serum
of animals challenged with the Asian lineage viruses (PRVABC59
and FSS13025), saliva and urine samples produced moderate
levels of viral load (<300 copies/mL). Lower viral loads in
saliva may be partly due to the dilution of swabs in PBS prior
to analysis. As expected, considering the serum viral load, the
animals challenged with the African strain IBH30656 resulted in
extremely low, sporadic amounts of detectable viral RNA levels
(Table 1).
Tissue Analysis
One testicle was harvested at 4 and 8 days p.i. from the
male of each cohort. The highest viral loads were consistently
detected from testes samples collected on day 8 post-inoculation.
Interestingly, the FSS13025 challenged male had the highest testes
viral load (Figure 2). Again consistent with the serum analysis,
no viral load was detected in the testes of animal challenged with
the African strain IBH30656. Upon study termination (60 days
p.i.) total brain samples were harvested from all animals. Multiple
tissue sections from each brain were tested for viral load by
qRT-PCR and all were negative for any residual viral genome
copies.
Neutralizing Antibody Response
Neutralizing antibodies (Nabs) following Zika challenge are
illustrated in Table 2. Sera collected on day 0 prior to challenge
were all negative (PRNT50 ≤ 10). The IBH30656 challenged
monkeys (5261 and 5257), that exhibited very low viral load
throughout study period, also failed to produce cross reactive
Nab to PRVABC59. The monkeys inoculated with the PRVABC59
and FSS13025 achieved high Nab titer to PRVABC59 by day 14.
Monkey 5262 that recorded highest viremia also attained highest
Nab titer of 7920. The day 14 Nab titers for these monkeys
ranged from 1,053 to 7,920. All four monkeys suffered a moderate
drop in titer on day 30 but Nab activity was persistent and
achieved titers ranging from 797 to 2,380. Notably, monkey
5262 (PRVABC59) and 5259 (FSS13025), that experienced more
apparent viremia rebound by 30 days p.i., attained >2-fold
higher Nab response than the other monkey in the same cohort
FIGURE 2 | Viral load in the testes of ZIKV infected cynomolgus
macaques. Viral load in the testes of cynomolgus macaques infected with
PRVABC59, FSS13025, or IBH30656 were detected by qRT-PCR on days 4
and 8 p.i. Multiple sections of each testicle were tested independently and
reported here are the sections with the highest viral load. ∗p-value < 0.05.
during this time. Nab titer was sustainable and all four macaques
achieved durable PRNT50 titers ranging from 528 ≥ 1,071 at
60 days p.i.
DISCUSSION
Arthropod-borne viruses such as the flaviviruses continue to
pose a significant threat to global health. The origin and
global spread of ZIKV during the ongoing pandemic is well-
documented (Dick et al., 1952; Duffy et al., 2009; Haddow
et al., 2012; Musso et al., 2014; Campos et al., 2015; Zanluca
et al., 2015; Solomon et al., 2016). The significance of ZIKV is
highlighted in the infection associated complications, such as
Guillain–Barre syndrome (Oehler et al., 2014; do Rosario et al.,
2016) and the risk of vertical transmission of the virus from
mother to the fetus, which can result in devastating lifelong
neurological complications including microcephaly (Brasil and
Nielsen-Saines, 2016; Martines et al., 2016; Mlakar et al., 2016;
Sarno et al., 2016). Considering the global health emergency
posed by ZIKV, there is an ongoing concerted effort among the
scientific community to develop new diagnostics, vaccines and
antivirals to stem the pandemic. Identification of cost effective
and robust animal models amenable to measuring viral load, viral
shedding and building cellular and humoral immune correlates
of vaccine efficacy is critical for the development of new vaccines
and therapeutics. Here, we report the results from a limited
study demonstrating the utility of cynomolgus macaques as a cost
effective alternative NHP animal model for the study of ZIKV
infection of Asian lineage.
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TABLE 2 | Development of anti-zika neutralizing antibodies following challenge.
Animal ID Challenge strain Dose (PFU) PRNT50 Titer
D2 D14 D30 D60
5262 M PRVABC59 5.0 × 105 <10 7920 2380 1071
5258 F PRVABC59 1.0 × 104 <10 2438 875 740
5260 M FSS13025 5.0 × 105 <10 1053 797 528
5259 F FSS13025 1.0 × 104 <10 3131 2019 666
5261 M IBH 30656 5.0 × 105 <10 <10 <10 <10
5257 F IBH 30656 1.0 × 104 <10 <10 <10 <10
Anti-PRVABC59 neutralizing antibodies were measured in serum collected at 2, 14, 30, and 60 days p.i. by standard PRNT assay. PRNT end-point titers are expressed
as the reciprocal of the last serum dilution showing the 50% reduction in plaque counts (PRNT50).
Failure of the African strain IBH30656 to produce a
significant viremia is in contrast to the previous work done
in rhesus macaques by the Wisconsin National Primate
Research Center2, where rhesus macaques developed a robust
viremia when challenged with the prototypic African strain,
Uganda MR766 (GenBank, LC002520, obtained from CDC,
Ft. Collins, CO, USA). In addition to the differences in
animal models, potentially significant genetic differences between
the two African lineage strains may exist. These differences
may encode changes leading to altered codon utilization
or post-translation processing which have been proposed to
play a role in ZIKV pathogenicity (Haddow et al., 2012;
Gupta et al., 2016; van Hemert and Berkhout, 2016). Indeed,
these two isolates have differences in passage history and
share only 93% identity at the nucleotide level. Heterogeneity
between available MR766 sequences makes genetic comparisons
with IbH30656 difficult (Haddow et al., 2012). Additional
studies are needed to further characterize the host and viral
factors involved in divergent pathogenicity between ZIKV
strains.
Interestingly, the Puerto Rican isolate PRVABC59 appeared
to provide the most robust infection, resulting in rapid systemic
serum viral load within the first 24 h p.i. (2.3 × 104 and
1.1 × 103 copies/mL) compared to the Cambodian FSS13025
isolate (6.4 × 102 and 5.0 × 102 copies/mL). The temporary lag
in amplification of the FSS13025 isolate may suggest different
replication kinetics between these two strains. In the rhesus
macaque model, peak plasma viremia occurred between 2 and
2https://zika.labkey.com/project/OConnor/ZIKV-002/begin.view
6 days p.i. and peak virus titer ranged from 8.2× 104 to 2.5× 106
RNA copies/mL after 1.0× 104 to 1.0× 106 challenge with Asian
strains (Dudley et al., 2016). Altogether, our study shows the peak
viral load was moderately lower in the cynomolgus macaque,
the duration and overall kinetics of virus replication produced
by Asian strains were similar to those observed in the rhesus
monkeys.
Recent bioinformatics and phylogenetic analyses, have
suggested the possible derivation of the currently circulating (in
the Americas) ZIKV pandemic isolates from the Asian lineage
(Brasil et al., 2016; Calvet et al., 2016; Lanciotti et al., 2016).
Furthermore, the sequences of clinical samples isolated from
the American outbreak are highly conserved, and are therefore
now recognized as a new clade of the Asian lineage (Enfissi et al.,
2016; Wang et al., 2016; Ye et al., 2016). Using genomic sequence
alignments, a comparison between historic Asian lineage isolates,
currently circulating American clade isolates and original African
lineage isolates demonstrates how divergent the American clade
has become from the African lineage (Table 3). In our study,
infection of NHPs with the African lineage virus (IBH30656)
did not elicit an immune response that cross-neutralized to
PRVABC59. This may be due to antigenicity difference between
African and Asian lineage viruses but most likely is due to the
failure of the virus to establish a productive infection. Numerous
studies have now been published on comparative genomics
and epidemiological analysis aimed at identifying critical
adaptive mutation(s) or processes such as codon utilization or
glycosylation that may contribute to the pathogenicity and/or
fitness in transmission of the emergent American clade (Gupta
et al., 2016; van Hemert and Berkhout, 2016; Ye et al., 2016).
TABLE 3 | Genomic sequence comparison of ZIKV isolates.
ZIKV Strain: Lineage/clade: MR-766 African IBH30656 African FSS13025 Asian PRVABC59 Asian ZKV2015 American
MR-766 ---- 93 89 89 89
IBH30656 93 ---- 88 88 88
FSS13025 89 88 ---- 98 98
PRVABC59 89 88 98 ---- 99
ZKV2015 89 88 98 99 ----
Pairwise comparison of nucleotide sequence using NCBI (https://blast.ncbi.nlm.nih.gov) Blastn sequence alignment tool. Strains of African and Asian lineage were
aligned with the newly emerging American Clade (Ye et al., 2016). ZKV2015 (Accession #KU497555.1) represents the American clade, the most clinically relevant strains
circulating in Brazil.
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Broad systemic infection of cynomolgus macaques with two
independent Asian lineage ZIKV isolates including one from the
current circulating pandemic, observed in our studies, suggest the
clinical relevance of this model. The failure to detect systemic
infection after challenge with the the Nigerian IBH30656 strain
of African lineage, is confounding, as other strains of the African
lineage (MR766) have been used in rhesus macaques and found
to produce robust infections in that animal model as stated above.
Whether this observation is limited to Nigerian IBH30656 or
more broadly, to other African isolates in cynomolgus macaques
need to be explored further.
Additionally, it would be of great interest to elucidate the
nature of the late recurrent viremia, now consistently seen in
both the cynomolgus and rhesus models reported previously
(Dudley et al., 2016). Although this “rebound virus” is eventually
cleared in the NHP animal models discussed, the identification
of tissue specific reservoir(s) for the rebound virus could lead to
mechanisms posing additional adaptive risks and changes in the
progression of the infection in humans, either through enhanced
transmission or potentially escalating clinical complications.
In the context of viral reservoirs, it is interesting to note that
the viral load of both PRVABC59 and FSS13025 in the testes at
8 days p.i. were higher in comparison to 4 days p.i. Importantly,
this is well after the serum viral load had peaked between 2
and 3 days p.i. This observation is consistent with previously
reported that male anatomical tissues have provided safe harbor
for persistent viral titers, long after symptoms and or systemic
viral load have resolved (Osuna et al., 2016).
Interestingly, Dudley et al. (2016) suggests that the viral
plasma “blips” seen after systemic clearance maybe the result of
viral seeding from these reservoirs. Importantly, understanding
tissue specific viral reservoirs and their role in providing for
mechanisms of viral adaptive immune escape would be critical
to the understanding of non-arthropod vectored transmission in
the current pandemic strain, and may provide strategic insights
for the development of new vaccines and therapeutics.
In this study, detection of serum and tissue viral load was
associated with the development of high functional Nab titers in
cynomolgus macaques infected with PRVABC59. These results
provide insight into the possibility of cynomolgus macaques
as an alternative model to study vaccine immunogenicity
and efficacy to decipher correlates of protective immunity. In
light of possible Zika-Dengue bi-directional antibody-dependent
enhancement (ADE) of disease (Dejnirattisai et al., 2016),
availability of surrogate animal models of both viruses to predict
safety and clinical benefit of candidate vaccines is essential.
Cynomolgus macaques have been established as a model for
Dengue virus infection and are currently be used for preclinical
safety and efficacy of vaccine candidates. The objective of this
study was to establish proof of concept Zika natural history
data in a limited number of cynomolgus monkey’s to justify
continued model development including an ADE model. Taken
together, our preliminary data supports continued development
of cynomolgus macaques as a model for ZIKV infection and
certainly warrant further investigation with more statistically
relevant numbers of animals. A cynomolgus macaque model
of ZIKV infection could be a useful tool to understand the
ZIKV natural infection, pathology and develop effective control
measures.
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